Particularly when an infant is born before 36 weeks'
gestation, the premature infant's lungs are immature,
and the body has limited muscle strength and energy for breathing. Therefore,
the premature infant may not get enough oxygen, which can cause serious medical
complications. It is common at birth for a premature infant to need oxygen
therapy, a ventilator machine, and/or medicine to help with oxygen absorption
and breathing.
Infants whose lungs have been quickly matured with corticosteroid treatment before birth (antenatal
corticosteroids, given by injection to the mother) have significantly fewer
medical complications than those who are not treated.1
Infants with underdeveloped lungs often lack surfactant, a substance that coats the airways, preventing
them from collapsing and sticking together. When premature lungs are treated
with surfactant after birth, the infant's blood oxygen levels usually improve
within minutes. Surfactant treatment reduces the risk and the severity of
respiratory distress syndrome (RDS) in premature
infants as well as the overall risk of death.2
Unlike corticosteroid treatment before birth, corticosteroid treatment after birth (postnatal) is losing
favor in the medical community. Current research is focusing on how this
medicine can be safely used to improve lung function without causing
neurological deficits, gastrointestinal bleeding and damage, blood sugar
problems, and high blood pressure. Postnatal corticosteroid treatment currently
is only recommended for infants whose lungs are so impaired that they cannot be
taken off ventilation.